Ceftobiprole: breaking therapeutic dogmas of the β-lactam class

Diagnostic Microbiology and Infectious Disease

Volumn 61, Issue 1, 2008, Pages 82-85

  Deresinski, Stanley C ^a,b  

^a STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

Author keywords

lactam; Antimicrobial; Ceftobiprole; Gram negative; Gram positive; MRSA; Staphylococcus aureus

Indexed keywords

BETA LACTAM; BETA LACTAMASE; CARBAPENEM DERIVATIVE; CEFAMANDOLE; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CEFTOBIPROLE; CEFTOBIPROLE MEDOCARIL; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; METICILLIN; PENICILLIN BINDING PROTEIN; PENICILLIN BINDING PROTEIN 2A; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL ARTHRITIS; BACTERICIDAL ACTIVITY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM PERFRINGENS; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG PROTEIN BINDING; DRUG SOLUBILITY; ENDOCARDITIS; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; FUSOBACTERIUM NUCLEATUM; HAEMOPHILUS INFLUENZAE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NAUSEA; PREVALENCE; PRIORITY JOURNAL; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA; RISK FACTOR; SERRATIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIAE; TASTE DISORDER; VOLUNTEER; VOMITING;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; CEPHALOSPORINS; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 41949137514     PISSN: 07328893     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2008.02.011     Document Type: Article

References (40)

1. Andes D.R., and Craig W.A. Cephalosporins. In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and Practice of Infectious Diseases. 6th ed (2005), Elsevier, Philadelphia, PA 294-311
2. Bogdanovich T., Clark C., Ednie L., Lin G., Smith K., Shapiro S., and Appelbaum P.C. Activities of ceftobiprole, a novel broad-spectrum cephalosporin, against Haemophilus influenzae and Moraxella catarrhalis. Antimicrob. Agents Chemother. 50 (2006) 2050-2057
3. Bozdogan B., Esel D., Whitener C., Browne F.A., and Appelbaum P.C. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J. Antimicrob. Chemother. 52 (2003) 864-868
4. Centers for Disease Control. Reduced susceptibility of Staphylococcus aureus to vancomycin-Japan, 1996. MMWR Morb. Mortal Weekly Rep. 46 (1997) 624-626
5. Chambers H.F. Ceftobiprole: in-vivo profile of a bactericidal cephalosporin. Clin. Microbiol. Infect. 12 Suppl 2 (2006) 17-22
6. Clinical and Laboratory Standards Institute (CLSI) (2007) Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. Vol. 27, No. 1. CLSI document M100-S17. Wayne, PA: CLSI.
7. Daum R.S. Clinical practice. Skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. N. Engl. J. Med. 357 (2007) 380-390
8. Davies T.A., Shang W., and Bush K. Activities of ceftobiprole and other β-lactams against Streptococcus pneumoniae clinical isolates from the United States with defined substitutions in penicillin-binding proteins PBP 1a, PBP 2b, and PBP 2x. Antimicrob. Agents Chemother. 50 (2006) 2530-2532
9. Deresinski S. Counterpoint: Vancomycin and Staphylococcus aureus- an antibiotic enters obsolescence. Clin. Infect. Dis. 44 (2007) 1536-1542
10. Deresinski S. Vancomycin: does it still have a role as an antistaphylococcal agent?. Expert. Rev. Anti Infect. Ther. 5 (2007) 393-401
11. Deshpande L., Rhomberg P.R., Fritsche T.R., Sader H.S., and Jones R.N. Bactericidal activity of BAL9141, a novel parenteral cephalosporin against contemporary Gram-positive and Gram-negative isolates. Diagn. Microbiol. Infect. Dis. 50 (2004) 73-75
12. Diep B.A., Chambers H.F., Graber C.J., Szumowski J.D., Miller L.G., Han L.L., Chen J.H., Lin F., Lin J., Phan T.H., Carleton H.A., McDougal L.K., Tenover F.C., Cohen D.E., Mayer K.H., Sensabaugh G.F., and Perdreau-Remington F. Emergence of multidrug-resistant, community-associated, methicillin-resistant Staphylococcus aureus clone USA300 in men who have sex with men. Ann. Intern. Med. 148 (2008) 249-257
13. Ednie L., Shapiro S., and Appelbaum P.C. Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin. Diagn. Microbiol. Infect. Dis. 58 (2007) 133-136
14. El-Shaboury S.R., Saleh G.A., Mohamed F.A., and Rageh A.H. Analysis of cephalosporin antibiotics. J. Pharm. Biomed. Anal. 45 (2007) 1-19
15. Entenza J.M., Hohl P., Heinze-Krauss I., Glauser M.P., and Moreillon P. BAL9141, a novel extended-spectrum cephalosporin active against methicillin-resistant Staphylococcus aureus in treatment of experimental endocarditis. Antimicrob. Agents Chemother. 46 (2002) 171-177
16. Frazee B.W., Lynn J., Charlebois E.D., Lambert L., Lowery D., and Perdreau-Remington F. High prevalence of methicillin-resistant Staphylococcus aureus in emergency department skin and soft tissue infections. Ann. Emerg. Med. 45 (2005) 311-320
17. Goldstein E.J., Citron D.M., Merriam C.V., Warren Y.A., Tyrrell K.L., and Fernandez H.T. In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections. Antimicrob. Agents Chemother. 50 (2006) 3959-3962
18. Golper T.A., Schulman G., and D'Agata E.M. Indications for vancomycin in dialysis patients. Semin. Dial. 13 (2000) 389-392
19. Hebeisen P., Heinze-Krauss I., Angehrn P., Hohl P., Page M.G., and Then R.L. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45 (2001) 825-836
20. Jones M.E. In-vitro profile of a new β-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus. Clin. Microbiol. Infect. 13 Suppl 2 (2007) 17-24
21. Jones R.N., Deshpande L.M., Mutnick A.H., and Biedenbach D.J. In vitro evaluation of BAL9141, a novel parenteral cephalosporin active against oxacillin-resistant staphylococci. J. Antimicrob. Chemother. 50 (2002) 915-932
22. King M.D., Humphrey B.J., Wang Y.F., Kourbatova E.V., Ray S.M., and Blumberg H.M. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144 (2006) 309-317
23. Kosowska K., Hoellman D.B., Lin G., Clark C., Credito K., McGhee P., Dewasse B., Bozdogan B., Shapiro S., and Appelbaum P.C. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin. Antimicrob. Agents Chemother. 49 (2005) 1932-1942
24. Micek S.T. Alternatives to vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis. 45 Suppl 3 (2007) S184-S190
25. Moreillon P., Que Y.A., and Glauser M.P. Staphylococcus aureus (including staphylococcal toxic shock). In: Mandell G.L., Bennett J.E., and Dolin R. (Eds). Principles and Practice of Infectious Diseases. 6th ed (2005), Elsevier, Philadelphia, PA 2321-2351
26. Mouton J.W., Schmitt-Hoffmann A., Shapiro S., Nashed N., and Punt N.C. Use of Monte Carlo simulations to select therapeutic doses and provisional breakpoints of BAL9141. Antimicrob. Agents Chemother. 48 (2004) 1713-1718
27. National Nosocomial Infections Surveillance (NNIS) System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am. J. Infect. Control 32 (2004) 470-485
28. Olesevich M., and Kennedy A. Emergence of community-acquired methicillin-resistant Staphylococcus aureus soft tissue infections. J. Pediatr. Surg. 42 (2007) 765-768
29. Ortho-McNeil-Janssen Pharmaceuticals, Inc. (2007) Data on file. Raritan, NJ.
30. Palavecino E. Community-acquired methicillin-resistant Staphylococcus aureus infections. Clin. Lab. Med. 24 (2004) 403-418
31. Pankuch G.A., and Appelbaum P.C. Postantibiotic effect of ceftobiprole against 12 Gram-positive organisms. Antimicrob. Agents Chemother. 50 (2006) 3956-3958
32. Petersen P.J., Jacobus N.V., Weiss W.J., Sum P.E., and Testa R.T. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob. Agents Chemother. 43 (1999) 738-744
33. Queenan A.M., and Bush K. Ceftobiprole (BAL9141): effect on AmpC beta-lactamase induction and resistance frequency in Gram-negative bacteria. Paper presented at: the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16-19, 2005; Washington, DC (2005)
34. Rossolini G.M. Redesigning β-lactams to combat resistance: summary and conclusions. Clin. Microbiol. Infect. 13 Suppl 2 (2007) 30-33
35. Rouse M.S., Hein M.M., Anguita-Alonso P., Steckelberg J.M., and Patel R. Ceftobiprole medocaril (BAL5788) treatment of experimental Haemophilus influenzae, Enterobacter cloacae, and Klebsiella pneumoniae murine pneumonia. Diagn. Microbiol. Infect. Dis. 55 (2006) 333-336
36. Rouse M.S., Steckelberg J.M., and Patel R. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection. Diagn. Microbiol. Infect. Dis. 58 (2007) 363-365
37. Schmitt-Hoffmann A., Nyman L., Roos B., Schleimer M., Sauer J., Nashed N., Brown T., Man A., and Weidekamm E. Multiple-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48 (2004) 2576-2580
38. Schmitt-Hoffmann A., Roos B., Schleimer M., Sauer J., Man A., Nashed N., Brown T., Perez A., Weidekamm E., and Kovács P. Single-dose pharmacokinetics and safety of a novel broad-spectrum cephalosporin (BAL5788) in healthy volunteers. Antimicrob. Agents Chemother. 48 (2004) 2570-2575
39. Ueda Y., and Sunagawa M. In vitro and in vivo activities of novel 2-(thiazol-2-ylthio)-1β-methylcarbapenems with potent activities against multiresistant gram-positive bacteria. Antimicrob. Agents Chemother. 47 (2003) 2471-2480
40. Wang G., Hindler J.F., Ward K.W., and Bruckner D.A. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44 (2006) 3883-3886